Perrigo Company plc
HealthcareNYSE:PRGO · New York Stock Exchange
+$0.09 today
Vol 2.50M · Avg 3.24M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$4.2B of revenue converted into -$1.8B of net income for the selected period. Gross margin is 34.2% and net margin is -42.3%, showing how much revenue survives after costs and taxes. EPS is $-13.11, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $4.3B -2.8% | $4.4B -6.1% | $4.7B +4.6% | $4.5B +7.6% | $4.1B | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $2.8B -2.5% | $2.8B -4.9% | $3.0B -0.7% | $3.0B +10.1% | $2.7B | $725.6M | $804.0M | $882.4M |
| Gross Profit | $1.5B -3.1% | $1.5B -8.2% | $1.7B +15.5% | $1.5B +2.8% | $1.4B | $8.9B | $7.6B | $6.2B |
| Gross Margin | 35.1% -0.1pp | 35.3% -0.8pp | 36.1% +3.4pp | 32.7% -1.5pp | 34.2% | 9.8% | 28.9% | 38.3% |
| Research & Development | $95.4M -15.0% | $112.2M -8.4% | $122.5M -0.5% | $123.1M +0.9% | $122.0M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $526.5M -52.7% | $1.1B -12.7% | $1.3B +5.3% | $1.2B +8.9% | $1.1B | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $1.2B -19.5% | $1.4B -6.5% | $1.5B +11.0% | $1.4B +36.9% | $1.0B | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $337.5M +3.6% | $325.9M -9.3% | $359.5M +6.2% | $338.6M +8.5% | $312.2M | $374.2M | $1.2B | $631.8M |
| EBITDA | -$797.9M -284.3% | $433.0M -17.5% | $525.0M +47.7% | $355.5M -48.9% | $695.9M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -18.8% -28.7pp | 9.9% -1.4pp | 11.3% +3.3pp | 8.0% -8.8pp | 16.8% | 5.6% | 46.3% | 42.0% |
| Operating Income | $343.3M +204.1% | $112.9M -25.7% | $151.9M +92.5% | $78.9M -80.8% | $410.4M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 8.1% +5.5pp | 2.6% -0.7pp | 3.3% +1.5pp | 1.8% -8.1pp | 9.9% | 16.6% | 24.1% | 22.0% |
| Interest Income | $0 | $0 | $0 | $0 | $0 | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $162.5M -13.5% | $187.8M +8.1% | $173.8M +11.4% | $156.0M +24.8% | $125.0M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$1.6B -747.7% | -$193.6M -20.8% | -$160.2M +26.5% | -$218.0M -43.7% | -$151.7M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$1.3B -1508.3% | -$80.7M -872.3% | -$8.3M +94.0% | -$139.1M -153.8% | $258.7M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -30.5% -28.7pp | -1.8% -1.7pp | -0.2% +2.9pp | -3.1% -9.4pp | 6.3% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $104.4M +30.5% | $80.0M +2151.3% | -$3.9M +52.4% | -$8.2M -102.1% | $389.6M | $1.3B | -$1.6B | $745.2M |
| Net Income | -$1.4B -729.7% | -$171.8M -1252.8% | -$12.7M +91.0% | -$140.6M -104.1% | -$68.9M | $4.9B | $4.8B | $4.7B |
| Net Margin | -33.5% -29.6pp | -3.9% -3.7pp | -0.3% +2.9pp | -3.2% -1.5pp | -1.7% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$10 -723.2% | -$1 -1231.2% | -$0 +90.3% | -$1 +1.0% | -$1 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$10 -723.2% | -$1 -1231.2% | -$0 +90.3% | -$1 +1.0% | -$1 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $138.5M +0.8% | $137.4M +1.6% | $135.3M +0.6% | $134.5M +0.7% | $133.6M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $138.5M +0.8% | $137.4M +1.6% | $135.3M +0.6% | $134.5M +0.7% | $133.6M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Scholar Rock Holding Corporation
NASDAQ:SRRK
$5.29B
Amicus Therapeutics, Inc.
FOLD
$4.55B
LivaNova PLC
NASDAQ:LIVN
$4.36B
Heartflow, Inc. Common Stock
NASDAQ:HTFL
$2.87B
Tarsus Pharmaceuticals, Inc.
NASDAQ:TARS
$2.67B
Supernus Pharmaceuticals, Inc.
NASDAQ:SUPN
$2.58B
Surgery Partners, Inc.
NASDAQ:SGRY
$2.00B
HUTCHMED (China) Limited
NASDAQ:HCM
$1.91B
Bausch Health Companies Inc.
NYSE:BHC
$1.89B
Alphatec Holdings, Inc.
NASDAQ:ATEC
$1.27B
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does PRGO generate?
Perrigo Company plc (PRGO) reported $4.25B of revenue in fiscal 2025.
Is PRGO profitable?
Perrigo Company plc (PRGO) reported -$1,425,400,000.00 of net income, with a net margin of -33.5%.
Explore More
Continue the stock analysis
Jump to another research area for this company.